Indian Journal of Respiratory Care

IJRC Email      Register      Login

VOLUME 12 , ISSUE 3 ( July-September, 2023 ) > List of Articles

Original Article

Clinical Characteristics and Outcomes of All Three COVID-19 Waves: A Single-center Experience

Kapil Alias M Chilana, Abinav Dagar, Suchira Chillana, Nandan Putti

Keywords : Coronavirus disease 2019, First wave, Management, Patient characteristics, Second wave, Third wave, Treatment outcomes, Vaccines

Citation Information : Chilana KA, Dagar A, Chillana S, Putti N. Clinical Characteristics and Outcomes of All Three COVID-19 Waves: A Single-center Experience. Indian J Respir Care 2023; 12 (3):234-238.

DOI: 10.5005/jp-journals-11010-1055

License: CC BY-NC-SA 4.0

Published Online: 30-10-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Context: With the growing incidence of cases in the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), there have been a number of spikes in the cases over the last 3 years and India has witnessed three waves of different strains of SARS-CoV2. Aims: The aim of this study was to evaluate the patient demographics, the population at risk, signs and symptoms presented, the effect of comorbidities, and treatment outcomes. Settings and design: Retrospective noninterventional observational study. Materials and methods: From January 2020 to February 2022, a study was carried out at Kalpana Chawla Government Medical College, Karnal, Haryana. The study included all inpatients above the age of 18 years who tested positive for COVID-19 through either a rapid antigen test (RAT) or reverse transcription-polymerase chain reaction (RT-PCR) from nasopharyngeal or oropharyngeal swabs. The sample size of the study was 300. Results: In all three waves, the incidence of COVID-19 was more common among men. The average age of patients was 39.8, 49, and 50 years in waves one, two, and three, respectively. Among various comorbidities, diabetes was the most prevalent, with 25, 33, and 29% of patients affected in waves one, two, and three, respectively. In the first wave, all patients received antiviral therapy, while in the second and third waves, 70 and 10% of patients were treated with antivirals, respectively. During the third wave, 60% of patients had received two doses of vaccine and 16% had received a single dose. Conclusion: The study provides insights into the patient characteristics, management, and treatment of COVID-19 patients in three different waves. Clinical significance: The study gives a bird's eye view of the treatment across the three waves and the evolution of management strategies. Also, the effectiveness of vaccination was seen in the third wave.

PDF Share
  1. Ciotti M, Angeletti S, Minieri M, et al. COVID-19 outbreak: an overview. Chemotherapy 2019;64(5-6):215–223. DOI: 10.1159/000507423
  2. Sarkar A, Chakrabarti AK, Dutta S. Covid-19 infection in India: a comparative analysis of the second wave with the first wave. Pathogens 2021;10(9):1222. DOI: 10.3390/pathogens10091222
  3. 2022. [online] Available at: [Accessed 30 May 2022].
  4. Fenollar F, Bouam A, Ballouche M, et al. Evaluation of the panbio COVID-19 rapid antigen detection test device for the screening of patients with COVID-19. J Clin Microbiol 2021;59(2):e02589-20. DOI: 10.1128/JCM.02589-20
  5. Sharma S, Basu S, Nagaraj P. et al. Aminabhavi, current treatment protocol for COVID-19 in India. Sens Int 2020;1:100013. DOI: 10.1016/j.sintl.2020.100013
  6. Gavriatopoulou, M, Ntanasis-Stathopoulos I, Korompoki E, et al. Emerging treatment strategies for COVID-19 infection. Clin Exp Med 2021;21(2):167–179. DOI: 10.1007/s10238-020-00671-y
  7. India: who coronavirus disease (covid-19) dashboard with vaccination data (no date). World Health Organization. Available at: (Accessed: 24 June 2023).
  8. Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect 2021;27(1):89–95. DOI: 10.1016/j.cmi.2020.09.023
  9. Zhou Y, Hou Y, Shen J, et al. A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19. PLOS Biology 2020;18(11):e3000970. DOI: 10.1371/journal.pbio.3000970
  10. Xiong Y, Sun D, Liu Y, et al. Clinical and high-resolution CT features of the COVID-19 infection: comparison of the initial and follow-up changes. Invest Radiol 2021;55(6):332–339. DOI: 10.1097/RLI.0000000000000674
  11. Jia JS, Lu X, Yuan Y, et al. Population flow drives spatio-temporal distribution of COVID-19 in China. Nature 2020;582(7812):389–394. DOI: 10.1038/s41586-020-2284-y
  12. Liu X, Huang J, Li C, et al. The role of seasonality in the spread of COVID-19 pandemic. Environ Res 2021;195:110874. DOI: 10.1016/j.envres.2021.110874
  13. Qi X, Liu Y, Wang J, et al. Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study. Gut 2021;70(2):433–436. DOI: 10.1136/gutjnl-2020-321666
  14. Wang C, Wang Z, Wang G, et al. COVID-19 in early 2021: current status and looking forward. Signal Transduct Target Ther 2021;6(1):114. DOI: 10.1038/s41392-021-00527-1
  15. Zhang H, Zang C, Xu Z, et al. Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat Med 2023;29(1):226–235. DOI: 10.1038/s41591-022-02116-3
  16. Li X, Zhong X, Wang Y, et al. Clinical determinants of the severity of COVID–19: a systematic review and meta–analysis. PLoS ONE 2021;16(5):e0250602. DOI: 10.1371/journal.pone.0250602
  17. Yang, J, Marziano, V, Deng X. et al. Despite vaccination, China needs non-pharmaceutical interventions to prevent widespread outbreaks of COVID-19 in 2021. Nat Hum Behav 2021;5(8):1009–1020. DOI: 10.1038/s41562-021-01155-z
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.